Toggle Main Menu Toggle Search

Open Access padlockePrints

Extreme Hodgkin's lymphoma: Current problem areas

Lookup NU author(s): Professor Stephen Proctor, Dr Jennifer Wilkinson


Full text for this publication is not currently held within this repository. Alternative links are provided below where available.


In Hodgkin's lymphoma therapy, there remain areas of extreme difficulty. This article briefly explores these areas and provides evidence that risk-related therapy and web-based data collection programmes can facilitate progress. Unpublished data from the northern region of the UK suggest that risk-based therapy among poor-prognosis Hodgkin's lymphoma patients aged 15-19 years is improving outcome. An index developed at the Memorial Sloan-Kettering Cancer Centre (MSKCC) for patients undergoing salvage therapy shows that new second-line regimens are urgently needed for those with poor prognosis. In primary therapy and relapse, both adolescent and adult patients with Hodgkin's lymphoma should receive treatment tailored to their degree of risk. Elderly patients with Hodgkin's lymphoma are also difficult to treat and fewer than 2% enter randomised clinical trials. We require new means of encouraging international pooling of data and treatment evaluation in such patients. The SHIELD project (Study of Hodgkin's lymphoma in the Elderly Lymphoma Database; is now successfully providing on-line registration in the ongoing phase II study of VEPEMB (vinblastine, cyclophosphamide, procarbazine, prednisolone, mitoxantrone and bleomycin) in the elderly and guidance on obtaining ethical approval for participation. © 2006 Oxford University Press.

Publication metadata

Author(s): Proctor SJ, Wilkinson J

Publication type: Conference Proceedings (inc. Abstract)

Publication status: Published

Conference Name: 9th International Conference on Malignant Lymphoma

Year of Conference: 2006

Pages: iv15-iv17

ISSN: 0923-7534

Publisher: Annals of Oncology, Oxford University Press


DOI: 10.1093/annonc/mdj993

PubMed id: 16702179

Library holdings: Search Newcastle University Library for this item

Sponsor(s): Baxter Oncology GmbH

ISBN: 15698041